Company Legal Name
Latest Valuation
Founded Year
Headquarter
Synchron, Inc. develops endovascular brain-computer interfaces that enable paralyzed patients to control digital devices through thought alone. Founded in 2012 and headquartered in Brooklyn, the company has pioneered a minimally invasive approach to brain-computer interface technology, utilizing blood vessels to access the brain rather than requiring open surgery. This endovascular method differentiates Synchron from competitors by reducing surgical risks and potentially accelerating patient adoption. The company's flagship technology translates neural signals into digital commands, allowing patients with severe paralysis to operate computers, smartphones, and other devices directly through mental intention. Synchron has achieved significant regulatory milestones, becoming the first company to receive FDA approval for a permanently implanted brain-computer interface in human patients. The technology addresses a substantial unmet medical need for individuals with conditions such as ALS, stroke, and spinal cord injuries. Synchron continues to advance clinical development while expanding its platform capabilities to serve the growing market for neural interface solutions.
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
How can I buy Synchron pre-IPO shares through Jarsy?
You can create an account, complete KYC verification, and start investing from just $10. Shares are fractionalized, so you can access pre-IPO opportunities without high entry barriers.
What is the current stock price and valuation of Synchron ?
The latest valuation of Synchron is , The live stock price chart shows historical price movements and company valuation trends. Investors can track performance before the IPO.
What is the minimum investment amount required to invest in Synchron ?
The minimum investment is $10, enabling fractionalized access to Synchron pre-IPO shares.
What fees will I pay when investing in Synchron pre-IPO shares?
Fees include platform fees and carried interest on realized profits.
What risks are involved in Synchron pre-IPO stock investments?
Risks include liquidity lock-ups, valuation uncertainty, industry-specific risks, regulatory changes, and potential custody or tokenization issues.
How does Jarsy ensure transparency of reserves and assets?
Each Jarsy issued Token is backed 1:1 by the economic rights of a corresponding share held by Jarsy’s Delaware LLC ( an LLC created for custody purposes). When a liquidation event happens, Jarsy would liquidate the shares and return the equivalent dollar value to token holders based on their economic interest. This structure ensures full transparency and direct backing of every token. All the supply and transactions information of the token can be verified independently through blockchain.
Can I sell my Synchron pre-IPO shares backed token before the IPO?
You may redeem your tokens through the Jarsy platform; however, settlement is not guaranteed and is subject to available liquidity and market demand.